Mebufotenin is under clinical development by Beckley Psytech and currently in Phase II for Treatment Resistant Depression. According to GlobalData, Phase II drugs for Treatment Resistant Depression have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mebufotenin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mebufotenin overview

BPL-003 is under development for the treatment of treatment resistant depression and alcohol use disorder. It is a benzoate formulation of 5-MeO-DMT and is administered through intranasal route as dry powder spray. The drug candidate is a potent and fast-acting psychedelic substance.

Beckley Psytech overview

Beckley Psytech is a biotech company. The company specializes in developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. Its psychedelic compounds include 5-MeO-DMT and psilocybin and psilocin which are associated with improvements in anxiety, mood, reduced stress, increased life satisfaction, mindfulness and other psychiatric disorders. The company also offers psychedelic-assisted psychotherapy for the people with severe mental health disorders. Beckley Psytech is headquartered in Oxford, England, the UK.

For a complete picture of Mebufotenin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.